Top Boston, MA Biotech Companies With Best Stability & Growth (306)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability, Growth & Resilience Strengths
Strategic Partnerships: Long‑running collaborations with Boehringer Ingelheim and Otsuka, plus a 2025 strategic investment from Dassault Systèmes/Medidata, reinforce scale and credibility. Evidence suggests these alliances provide development resources, commercialization pathways, and platform reach.
Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD; CT‑132 for preventive episodic migraine) and the acquisition of AspyreRx expand the portfolio across psychiatry, neurology, and cardiometabolic care. Late‑stage CT‑155 Phase 3 success and Breakthrough Device status add pipeline depth.
Investor Backing & Capital Strength: Recent fundraising and M&A momentum amid a consolidating market indicate access to capital and financial resilience. This capital base supports evidence generation, scaling, and entry into new categories.
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability, Growth & Resilience Strengths
Strong Revenue Growth: Recent updates describe accelerating revenue and record platform analyses, and guidance indicates continued top-line expansion.
Strategic Partnerships: High-profile collaborations with Memorial Sloan Kettering, AstraZeneca, and major U.S. health systems are enabling decentralized liquid biopsy and comprehensive genomic profiling rollouts across its installed base.
Strong Market Position & Advantage: The company is characterized as a category leader in decentralized, cloud-native genomics analytics with a broad global hospital network and extensive cumulative profiles analyzed.
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability, Growth & Resilience Strengths
Strong Market Position & Advantage: Benchling is widely viewed as a leader for cloud‑native R&D data platforms in discovery and early development, with named rollouts at major biopharma. Feedback suggests its integrated, cloud‑first approach and brand visibility keep it on enterprise shortlists across biotech R&D.
Innovation-Driven Growth: The company is actively expanding capabilities with AI (e.g., Benchling AI), new modules like Bioprocess, and acquisitions such as PipeBio to strengthen biologics workflows. Feedback suggests this product velocity supports ongoing expansion and differentiation versus legacy tools.
Strategic Partnerships: Expanded collaborations with marquee pharmas (e.g., Moderna) and broad deployments at companies like Sanofi indicate deepening enterprise ties. Feedback suggests these relationships create durable upsell paths and reinforce long‑term account penetration.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability, Growth & Resilience Strengths
Strong Market Position & Advantage: Broad adoption across large pharma and recognition as a leader in physics‑based discovery software indicate a durable competitive edge, reinforced by flagship tools like Glide and FEP+ with peer‑reviewed validation. Penetration across all top global pharma and sticky, long‑tenure accounts suggest standard‑tool status in discovery teams.
Strong Revenue Growth: Recent results show higher software revenue and total revenue growth in 2025, with guidance pointing to continued expansion in software ACV in 2026. Management frames software as the scaled growth engine while hosted deployments rise.
Strategic Partnerships: Large, multi‑year collaborations with major pharmas and long‑running technical work with NVIDIA support pipeline upside and platform performance. Deal structures with upfronts, milestones, and potential royalties diversify growth levers.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability, Growth & Resilience Strengths
Strong Revenue Growth: Reported revenue accelerated sharply year over year with continued guidance for expansion, and quarterly results showed momentum across both diagnostics and data businesses. Total remaining contract value and rising spend among existing customers support durability.
Strategic Partnerships: Multi‑year collaborations with leading biopharma and health systems, along with an international joint venture, signal deep ecosystem integration. These agreements include substantial data licensing and model‑development components that reinforce platform adoption.
Strong Market Position & Advantage: An FDA‑approved NGS companion diagnostic, broad provider reach across many U.S. academic medical centers, and a scaled multimodal oncology dataset underpin positioning as a leader in AI‑enabled precision oncology. Public‑company status and expanding trial‑matching capabilities further reinforce this standing.
Synterex is a woman-owned, disability-owned business that provides clinical solutions, including publishing, clinical science, project management, medical and regulatory writing services, and IT collaboration services, from process development and optimization to document production. Our staffers are seasoned and dedicated, with extensive experience doing the work hands-on as well as building and leading teams. We are committed to applying our years of...
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPE Platform enables massively multiplexed,...
ArkeaBio is a global agricultural bioscience company developing a safe, cost-effective vaccine to reduce methane emissions from cattle all over the world. We are the first to successfully demonstrate a proof-of-concept vaccine. It’s the safest, most cost-effective solution for reducing greenhouse gas emissions in agriculture, and it’s the only one that can be quickly and sustainably scaled to reach all...
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for...
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space. Where lab construction can take 9 to 12 months in the traditional process, we deliver personalized and effective lab workflow environments in about 4 weeks. This huge reduction in time means member teams are starting sooner and results are delivered...
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes. The Company’s science is targeting immune-excluded tumors, an identifiable, prevalent solid tumor phenotype. Incendia’s unique approach breaks down physical and biochemical barriers within the TME to enhance host immune cell infiltration into tumors and enable cancer therapeutics...
As Lentiviral vectors have transformed medicine with their safety and efficacy, they have created a demand for production that far exceeds current capacity. Traditional manufacturing systems have seen long wait times and critical raw material shortages cause delays in development and deployment of these life-altering therapies. Our Intelligent Vector Solutions(TM) can be used to manufacture ANY LENTI, ANY SCALE(TM) to provide our...
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new...
Driven by science and passionate about advancing patient care, DynamiCure is translating breakthrough insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential to treat cancer, autoimmune, and other diseases. Our core values - Empathy, Dedication, Collaboration, Transparency - are at the heart of everything we do, inspired by each other and our partners to...
For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 3,500 employees in 28 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience,...
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Jnana’s wholly owned lead program is a potential first-in-class...
We are a pioneering life sciences MLOps company for the future that transforms biological discovery by integrating different forms of biomedical data. We support discovery programs at Pfizer, Bristol Myers Squibb, Genentech, Stanford and Yale and have 35+ research partners from premier biopharma companies and research labs. We are a 150+ multi-disciplinary team of experts based across the US, Canada,...




































